Global Leading Market Research Publisher QYResearch announces the release of its latest report "Injection of Fat Dissolving Needle - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032". Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Injection of Fat Dissolving Needle market, including market size, share, demand, industry development status, and forecasts for the next few years.

For medical aesthetic practitioners, dermatologists, and plastic surgeons, non-surgical body contouring options that offer localized fat reduction with minimal downtime have become increasingly sought after by patients avoiding invasive liposuction. The global Injection of Fat Dissolving Needle market addresses this need through minimally invasive treatments that directly inject specific fat-degrading drugs (phosphatidylcholine, deoxycholic acid) into areas of localized fat accumulation. The principle involves inducing fat cell rupture and dissolution, with degraded cells naturally excreted through the body's metabolism—achieving localized body shaping and fat thickness reduction. As demand for non-surgical aesthetic procedures continues to rise globally, the fat dissolving injection market is experiencing rapid growth.

The global market for Injection of Fat Dissolving Needle was estimated to be worth US$ 383 million in 2025 and is projected to reach US$ 1365 million, growing at a CAGR of 20.2% from 2026 to 2032. In 2024, global production reached 638,000 units, with an average selling price of US$ 600 per unit. This explosive growth reflects the increasing preference for minimally invasive aesthetic treatments.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097479/injection-of-fat-dissolving-needle

Non-Surgical Adipocyte Disruption for Localized Fat Reduction
Lipolysis injections are a medical aesthetic product or treatment that uses a minimally invasive method to directly inject specific fat-degrading drugs (such as phosphatidylcholine and deoxycholic acid) into areas of localized fat accumulation. The principle is to induce the rupture and dissolution of fat cells through the drug, which are then naturally excreted through the body's metabolism, thereby achieving localized body shaping and reducing fat thickness. This method is typically used to treat areas of localized fat accumulation, such as the face, chin, abdomen, and arms. It is characterized by its ease of use, short recovery period, and minimal invasiveness. However, it must be performed under the guidance of a professional physician to ensure safety and effectiveness.

The primary advantage over surgical liposuction includes no incisions, no general anesthesia, reduced downtime (often 1-3 days), and lower risk of contour irregularities. Typical treatment requires 2-4 sessions spaced 4-8 weeks apart. The submental (double chin) area is the most common treatment site, with the U.S. FDA approving deoxycholic acid (Kybella) specifically for this indication.

Industry Segmentation: Active Ingredients & Applications
The Injection of Fat Dissolving Needle market is segmented by active pharmaceutical ingredient and treatment facility type:

Phosphatidylcholines: One of the original fat-dissolving agents, often combined with deoxycholic acid. Phosphatidylcholine-based injections have been used for decades in aesthetic medicine.

Deoxycholic Acid: A synthetic bile acid that disrupts adipocyte cell membranes. Deoxycholic acid is the only FDA-approved injectable fat-dissolving agent (brand name Kybella, AbbVie), specifically indicated for submental fat (double chin). A major medical aesthetics chain reported that deoxycholic acid injections account for over 60% of its non-surgical body contouring revenue.

Compound Lipolysis Injection: Custom-compounded formulations combining multiple active ingredients. These are used primarily in markets where branded products are not available or for off-label applications.

Application Segments
Medical Beauty Institutions: Aesthetic clinics, medispas, and dermatology practices represent the largest and fastest-growing application segment. A leading medispa franchise reported that fat dissolving injections increased patient retention rates by 35% compared to single-session procedures.

Hospitals: Plastic surgery and dermatology departments offer fat dissolving injections as an outpatient alternative to liposuction.

Others: Wellness centers and integrated aesthetic practices.

Technology Developments & Market Trends
Over the past six months, several advancements have shaped the market. Needle-free injection devices are emerging for fat dissolving applications, reducing patient discomfort. Combination protocols with radiofrequency or cryolipolysis are being developed to enhance results. Extended-release formulations may reduce required treatment sessions.

The trend toward combination treatments (fat dissolving injections + skin tightening) is growing for body contouring applications. Off-label use for other body areas (bra fat, knee fat, love handles) continues to expand despite regulatory indications limited to submental area in the U.S. Patient demand for "lunchtime procedures" with minimal downtime has accelerated adoption.

Regional Market Dynamics
North America leads the fat dissolving needle market, driven by FDA approval of deoxycholic acid, high disposable income, and strong medical aesthetics culture. The United States dominates with significant off-label use beyond submental indications.

Europe follows closely, with strong adoption in Germany, France, and the UK, where compound lipolysis injections are more widely used. Asia-Pacific is the fastest-growing region, with rising middle-class spending on aesthetics, increasing medical tourism, and expanding beauty clinic infrastructure in China, South Korea, Japan, and Thailand.

Competitive Landscape
Key players include AbbVie (Allergan), Bausch Health, Mastelli, LINACOS, LipoCure, Lipo Vela, Mesoestetic, Revitacare, Toskani, and Hugel.

Market Segmentation
The Injection of Fat Dissolving Needle market is segmented as below:

By Company

AbbVie

Bausch Health

Mastelli

LINACOS

LipoCure

Lipo Vela

Mesoestetic

Revitacare

Toskani

Hugel

Segment by Type

Phosphatidylcholines

Deoxycholic Acid

Compound Lipolysis Injection

Segment by Application

Medical Beauty Institutions

Hospitals

Others

Exclusive Industry Outlook
Looking ahead, the convergence of fat dissolving needle technology with combination therapies, novel formulations, and personalized treatment protocols represents a significant growth frontier. Development of PLLA (poly-L-lactic acid) and calcium hydroxylapatite combined with fat dissolving agents may provide simultaneous volume restoration. Improved patient comfort technologies (vibration, cooling, micro-needle arrays) will enhance the treatment experience. Regulatory expansion of approved indications beyond submental fat will open new market segments. The ability to offer injection of fat dissolving needle products that combine efficacy, safety, and patient satisfaction—supported by physician training and clinical data—will define competitive differentiation.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp